# The 'Workout Pill’ Is Finally Here – Here's What It Does

Source: https://www.youtube.com/watch?v=jCMi7TRNSDI
Recap page: https://rapidrecap.app/video/jCMi7TRNSDI
Generated: 2025-11-12T02:32:40.738+00:00

---
## Quick Overview

Azelprag, an oral apelin receptor activator, is predicted to hit the market around 2028, offering significant fat loss (potentially 1 lb/week extra) and muscle preservation benefits, even in sedentary individuals, by enhancing metabolic expenditure and preventing muscle loss during rest, though users must monitor for mild GI upset and transient headaches.

**Key Points:**
- Azelprag is a first-in-class oral activator of the apelin (APL1) receptor, mimicking the effects of exercise-induced apelin.
- Pre-clinical data suggests Azelprag can cause significant fat loss (up to 1 lb/week extra over 12 weeks in sedentary adults) while preserving lean tissue.
- The drug turns skeletal muscle into a 'higher-octane furnace,' spiking glucose uptake and fatty-acid oxidation, thus shifting the energy balance toward net burn.
- In older adults during a 10-day bed-rest study, Azelprag prevented roughly 30% of expected muscle loss and kept protein synthesis markers elevated.
- Azelprag also acts as a vasodilator, improving nutrient delivery to muscles and increasing baseline calorie expenditure, which is similar to the effects of light endurance work.
- The combination of Tirzepatide (appetite control) and Azelprag (expenditure increase) is projected to be highly effective, hitting the market around 2028.
- Reported side effects are generally mild and short-lived, including mild GI upset (nausea, loose stool) and transient headaches, with liver enzyme elevation seen in 5% of subjects in one obesity trial.

![Screenshot at 0:42: Dr. Mike introduces the topic by presenting the on-screen graphic titled 'THE "EXERCISE PILL" IS FINALLY HERE!' to frame the discussion about Azelprag.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-00-42.png)

**Context:** Dr. Mike from RP Strength discusses Azelprag, a novel compound being developed as a potential 'exercise pill.' The discussion focuses on its mechanism of action as an oral apelin receptor agonist, comparing its effects to those naturally achieved through exercise. He reviews early data suggesting strong efficacy in fat loss and muscle preservation, particularly in sedentary states, and contrasts its mechanism with other weight-loss drugs like Tirzepatide.

## Detailed Analysis

Dr. Mike introduces Azelprag as an 'exercise pill' that acts as a first-in-class oral activator of the apelin (APL1) receptor, mimicking the signaling switch flipped by exercise. He explains that Azelprag causes skeletal muscle to function like a 'higher-octane furnace,' increasing glucose uptake and fatty-acid oxidation, leading to fat burning even without exercise. Data suggests this mechanism leads to significant fat loss (modeling suggests 4-6 lbs over 12 weeks in sedentary adults just from a ~100 kcal/day increase in basal metabolic rate) while preserving muscle mass. A 10-day bed-rest study on older adults showed Azelprag prevented about 30% of expected muscle loss and maintained protein synthesis markers. Furthermore, Azelprag is a vasodilator, which improves nutrient delivery and increases calorie expenditure, mimicking exercise effects. When stacked with Tirzepatide (which controls appetite), the combination is projected to be highly effective, potentially hitting the market around 2028. Side effects observed were mild, primarily GI upset and transient headaches, though one large obesity trial showed elevated liver enzymes in 5% of subjects, leading to the study's redesign. Dr. Mike concludes that the combination of diet, training, supplements, and pharmacology, rather than relying on one drug alone, is the best approach, but he anticipates Azelprag will be safe and effective when used correctly.

### Azelprag Mechanism

- First-in-class oral activator of the apelin (APL1) receptor
- Mimics the signaling switch flipped by the 'exercise' apelin that floods the bloodstream during training
- Activates apelin receptor (APJ) which is also activated by apelin, leading to increased energy expenditure.

### Fat Loss & Muscle Preservation Effects

- Turns skeletal muscle into a higher-octane furnace (glucose uptake/fatty-acid oxidation spike)
- Prevents nearly 30% of muscle loss in older adults during 10-day bed rest
- Results in 4-6 lbs of extra fat loss over 12 weeks in sedentary adults just by increasing basal metabolic rate by ~100 kcal/day.

### Side Effects and Safety

- Mild GI upset (nausea, loose stool) and transient headaches were common but generally short-lived
- One obesity trial flagged elevated liver enzymes in ~5% of subjects, prompting the trial halt/redesign
- Blood pressure drops are expected due to vasodilation, which is common but rarely symptomatic.

### Future Outlook & Stacking

- Combination with Tirzepatide (appetite control) is predicted to be highly effective, hitting the market around 2028
- Drugs like Myostatin, Activin, Amylin, Apelin, and LOADS antagonists are arriving soon
- RP's approach is to use these drugs synergistically with diet and training, not as a replacement.

![Screenshot at 0:01: The speaker, Dr. Mike, introduces the topic of performance-enhancing compounds as the 'era of enhancement.'](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-00-01.png)
![Screenshot at 0:42: Title card appears: 'THE "EXERCISE PILL" IS FINALLY HERE! HERE'S WHAT IT DOES BY DR. MIKE ISRAEL' setting the stage for the discussion on Azelprag.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-00-42.png)
![Screenshot at 1:13: On-screen text details Azelprag is a first-in-class oral activator of the apelin \(APL1\) receptor.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-01-13.png)
![Screenshot at 2:05: Visual text highlights Azelprag turns skeletal muscle into a 'higher-octane furnace' for glucose uptake and fatty-acid oxidation.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-02-05.png)
![Screenshot at 3:07: On-screen text details the mechanism: turning skeletal muscle into a high-octane furnace, nudging energy balance toward net burn even without more movement.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-03-07.png)
![Screenshot at 4:33: On-screen text shows pre-clinical obesity models retained ~2x more weight when apelin signaling was boosted, indicating muscle preservation.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-04-33.png)
![Screenshot at 6:36: The speaker gestures while explaining that Azelprag is a small molecule taken orally, avoiding infusion clinics.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-06-36.png)
![Screenshot at 8:11: New slide appears: 'HOW DOES IT HELP BUILD OR SPARE MUSCLE?' introducing the next section.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-08-11.png)
![Screenshot at 10:10: Graphic displays the apelin signaling cross-talks with AMPK and Akt/mTOR, tipping the scale toward 'build' rather than 'break' even in a calorie deficit.](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-10-10.png)
![Screenshot at 13:14: The speaker transitions to discussing side effects, noting they are not 'terrible.' Side effects include mild GI upset and transient headaches \(13:16\). The first big obesity trial flagged elevated liver enzymes in 5% of subjects \(13:37\). This prompted the trial to halt and redesign \(13:44\). The speaker mentions the potential for users to feel dizzy due to mild vasodilation \(14:20\). The expected side effects are manageable through lifestyle adjustments like proper hydration and salt intake \(15:34\). The speaker clarifies that the liver enzyme issue was dose-dependent and protocols test lower peaks \(14:58\). The combination of drugs is predicted to cause GI stress, requiring careful management \(15:29\). The speaker gives a thumbs up to the low risk of severe side effects like hypoglycemia or suicidal ideation \(15:55\). \(This is a summary of the two side effect points\). The speaker is shown giving a thumbs up and thumbs down gesture \(10:54\) to illustrate the low risk of severe side effects compared to other weight-loss agents that cause muscle loss \(10:57\). The speaker discusses the importance of diet/training even with the drug, noting the risk of muscle loss \(11:11\). \(This is a summary of the muscle sparing point\). The speaker is shown gesturing with both hands wide apart \(11:51\) to emphasize the magnitude of the benefits \(11:54\). The speaker then presents a slide regarding future outlook \(23:44\). The speaker predicts the market will see many effective fat loss/muscle gain drugs hitting the market around 2028 \(23:50\). The speaker points out that the apelin agonist \(Azelprag\) will likely be one of the first major oral players \(24:48\). The combination of Tirzepatide and Azelprag is projected to cause significant fat loss while preserving lean tissue \(24:43\). The speaker concludes by emphasizing that diet and training are still necessary, and this drug is an additive tool, not a magic pill \(27:35\). The video ends with an RP branded outro screen \(28:25\).](https://ss.rapidrecap.app/screens/jCMi7TRNSDI/00-13-14.png)